4-Amino-2-methylquinolineCAS# 6628-04-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 6628-04-2 | SDF | Download SDF |
PubChem ID | 81116 | Appearance | Powder |
Formula | C10H10N2 | M.Wt | 158 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-methylquinolin-4-amine | ||
SMILES | CC1=NC2=CC=CC=C2C(=C1)N | ||
Standard InChIKey | COCFIBRMFPWUDW-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C10H10N2/c1-7-6-9(11)8-4-2-3-5-10(8)12-7/h2-6H,1H3,(H2,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
4-Amino-2-methylquinoline Dilution Calculator
4-Amino-2-methylquinoline Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.3291 mL | 31.6456 mL | 63.2911 mL | 126.5823 mL | 158.2278 mL |
5 mM | 1.2658 mL | 6.3291 mL | 12.6582 mL | 25.3165 mL | 31.6456 mL |
10 mM | 0.6329 mL | 3.1646 mL | 6.3291 mL | 12.6582 mL | 15.8228 mL |
50 mM | 0.1266 mL | 0.6329 mL | 1.2658 mL | 2.5316 mL | 3.1646 mL |
100 mM | 0.0633 mL | 0.3165 mL | 0.6329 mL | 1.2658 mL | 1.5823 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6'-O-Acetylpaniculoside II
Catalog No.:BCC8316
CAS No.:
- Stemonidine
Catalog No.:BCC8253
CAS No.:66267-46-7
- N-dotriacontanol
Catalog No.:BCC8218
CAS No.:6624-79-9
- N-Benzylanthranilic acid
Catalog No.:BCC9093
CAS No.:6622-55-5
- Cyromazine
Catalog No.:BCC5328
CAS No.:66215-27-8
- Deacetylxylopic acid
Catalog No.:BCN4210
CAS No.:6619-95-0
- Malic acid 4-Me ester
Catalog No.:BCN4209
CAS No.:66178-02-7
- Cimicifugoside
Catalog No.:BCN2623
CAS No.:66176-93-0
- Chromolaenide
Catalog No.:BCN7341
CAS No.:66148-25-2
- Levalbuterol tartrate
Catalog No.:BCC4217
CAS No.:661464-94-4
- 14,17-Epidioxy-28-nor-15-taraxerene-2,3-diol
Catalog No.:BCN1386
CAS No.:66107-60-6
- Pergolide mesylate
Catalog No.:BCC4464
CAS No.:66104-23-2
- Gomisin J
Catalog No.:BCN2270
CAS No.:66280-25-9
- Pregomisin
Catalog No.:BCN7000
CAS No.:66280-26-0
- 3H-1,2-Benzodithiol-3-one-1,1-dioxide
Catalog No.:BCC8633
CAS No.:66304-01-6
- ML 171
Catalog No.:BCC6252
CAS No.:6631-94-3
- Dihydroguaiaretic acid
Catalog No.:BCN4212
CAS No.:66322-34-7
- 5'-Deoxy-5-fluorocytidine
Catalog No.:BCC8746
CAS No.:66335-38-4
- Ranitidine
Catalog No.:BCC9134
CAS No.:66357-35-5
- Ranitidine Hydrochloride
Catalog No.:BCC4533
CAS No.:66357-59-3
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
- Methylsyringol
Catalog No.:BCN3535
CAS No.:6638-05-7
- (+)-Apogossypol
Catalog No.:BCC5585
CAS No.:66389-74-0
- Chloranthalactone A
Catalog No.:BCN8022
CAS No.:66395-02-6
Matrix-assisted laser desorption/ionization matrices for negative mode metabolomics.[Pubmed:23841224]
Eur J Mass Spectrom (Chichester). 2013;19(1):39-47.
Matrix-assisted laser desorption/ionization (MALDI) has been shown to be highly sensitive for analyzing low-mass compounds such as metabolites if the right matrix is used. 9-aminoacridine (9AA) is the most commonly employed matrix for negative mode MALDI-MS in metabolomics. However, matrix interferences and the strongly varying sensitivity for different metabolites make a search for alternative matrices desirable, in order to identify compounds with a different chemical background and/or favoring a different range of analytes. We tested the performance of a series of potential negative mode MALDI matrices with a mix of 29 metabolites containing amino acids, nucleotide phosphates and Krebs cycle intermediates. While ethacridine lactate was found to provide limits of detection (LODs) in the low femtomole range for nucleotide phosphates, amino acids and Krebs cycle intermediates in the low picomole range, 4-Amino-2-methylquinoline showed LODs in the picomole range for most metabolites, but is capable of ionizing a broader range of analytes than both 9AA and ethacridine.
Ab initio, density functional theory and structural studies of 4-amino-2-methylquinoline.[Pubmed:19581121]
Spectrochim Acta A Mol Biomol Spectrosc. 2009 Oct 1;74(2):375-84.
The Fourier transform infrared (FTIR) and FT-Raman spectra of 4-Amino-2-methylquinoline (AMQ) have been recorded in the range 4000-400 and 4000-100 cm(-1), respectively. The experimental vibrational frequency was compared with the wavenumbers obtained theoretically by ab initio HF and DFT-B3LYP gradient calculations employing the standard 6-31 G** and high level 6-311 ++G** basis sets for optimised geometry of the compound. The complete vibrational assignment and analysis of the fundamental modes of the compounds were carried out using the experimental FTIR and FT-Raman data, and quantum mechanical studies. The geometry and normal modes of vibration obtained from the HF and DFT methods are in good agreement with the experimental data. The potential energy distribution of the fundamental modes was calculated with ab initio force fields utilising Wilson's FG matrix method. The NH-pi interactions and the influence of amino and methyl groups on the skeletal modes are investigated.
Plasmodium berghei: in vitro and in vivo activity of dequalinium.[Pubmed:16814285]
Exp Parasitol. 2007 Jan;115(1):19-24.
Bisquinoline compounds have exhibited remarkable activity in vitro and in vivo against Plasmodium parasites by inhibition of heme detoxification. We have tested the ability of dequalinium 1,1'-(1,10-decanediyl)bis(4-Amino-2-methylquinoline), a known antimicrobial agent, to inhibit beta-hematin synthesis using a non-emzymatic colorimetric assay and globin proteolysis by electrophoretic analysis (SDS-PAGE-15%). Dequalinium was able to inhibit both processes in vitro with close correlation to a murine malaria model, reducing parasitemia levels, prolonging the survival time post-infection and curing 40% of infected mice using a combination therapy with a loading dose of chloroquine. These results confirm that dequalinium is a promising lead for antimalarial drug development.
A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists.[Pubmed:15571866]
Eur J Med Chem. 2004 Dec;39(12):1047-57.
A series of 4-Amino-2-methylquinoline and 4-aminoquinazoline derivatives, including the reference NOP antagonist JTC-801, were synthesized by an alternative pathway and their in vitro pharmacological properties were investigated. 3-Substitution of the quinoline ring resulted very critical for affinity. So 3-methyl derivative 4j showed a similar potency compared with the reference 4h while bulky lipophilic or electron withdrawing groups in the same position strongly decreased affinity. Structural and conformational requirements for affinity were outlined by NOE NMR and computational methods and suggestions for a pharmacophore model design were provided.